Compare FIVN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | INVA |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2014 | 2004 |
| Metric | FIVN | INVA |
|---|---|---|
| Price | $18.16 | $19.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 5 |
| Target Price | $31.53 | ★ $36.80 |
| AVG Volume (30 Days) | ★ 1.9M | 630.7K |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | 0.37 | ★ 1.52 |
| Revenue | ★ $1,127,466,000.00 | $388,521,000.00 |
| Revenue This Year | $12.29 | $13.23 |
| Revenue Next Year | $9.40 | $8.58 |
| P/E Ratio | $50.24 | ★ $12.93 |
| Revenue Growth | ★ 12.48 | 10.14 |
| 52 Week Low | $16.96 | $16.52 |
| 52 Week High | $49.90 | $22.76 |
| Indicator | FIVN | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 47.64 |
| Support Level | $16.96 | $19.42 |
| Resistance Level | $19.51 | $19.90 |
| Average True Range (ATR) | 0.89 | 0.42 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 38.91 | 64.42 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.